Sponsors / SUPN
SUPN

Supernus Pharmaceuticals, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
26Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsNCT00626236SUPNPhase 2Completed2009-09-23Actual
Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionNCT02285504SUPNPhase 2Completed2015-06-05Actual
A Study With SAGE-547 for Super-Refractory Status EpilepticusNCT02477618SUPNPhase 3Completed2017-07-18Actual
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionNCT02614547SUPNPhase 2Completed2016-06-22Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)NCT02618408SUPNPhase 3Completed2019-09-04Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)NCT02618434SUPNPhase 3Completed2019-11-15Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)NCT02691182SUPNPhase 3Terminated2021-05Actual
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)NCT02736656SUPNPhase 3Active not recruiting2026-09Estimated
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)NCT02942004SUPNPhase 3Completed2017-09-24Actual
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)NCT02942017SUPNPhase 3Completed2017-09-17Actual
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentNCT03597503SUPNPhase 3Terminated2020-01-22Actual
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDNCT03638466SUPNPhase 2Terminated2019-11-07Actual
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)NCT03665038SUPNPhase 3Completed2021-01-08Actual
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDNCT04143217SUPNPhase 3Completed2022-07-26Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)NCT04476017SUPNPhase 2Completed2022-03-25Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624SUPNPhase 2Completed2021-09-28Actual
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)NCT05107128SUPNPhase 2Completed2024-09-04Actual
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentNCT05318937SUPNPhase 2Completed2024-01-17Actual
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseNCT05358821SUPNPhase 2Completed2024-02-29Actual
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyNCT05518578SUPNPhase 2Recruiting2027-12-31Estimated
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT05619692SUPNPhase 2Completed2024-06-05Actual
An Open-Label Study Evaluating Brexanolone in Adults With TinnitusNCT05645432SUPNPhase 2Completed2023-11-21Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseNCT05655520SUPNPhase 3Terminated2025-01-20Actual
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresNCT06798896SUPNPhase 2Recruiting2027-08Estimated
SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329SUPNPhase 2Recruiting2027-12-31Estimated
Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661SUPNPhase 2Recruiting2026-12-31Estimated

Latest recorded trial changes